NCT05354713View on ClinicalTrials.gov

NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers (BE)

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

November 5, 2022

Primary Completion Date

March 20, 2023

Study Completion Date

April 27, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

NVP-1805

NVP-1805 (80/10/20.8mg)

DRUG

NVP-1805-R1 and NVP-1805-R2

coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10/20.8mg)

Trial Locations (1)

Unknown

H Plus Yangji Hospita, Seoul

Sponsors

Lead Sponsor

NVP Healthcare
All Listed Sponsors
lead

NVP Healthcare

INDUSTRY

NCT05354713 - NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers (BE) | Biotech Hunter | Biotech Hunter